Shen S - Search Results

1

Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma.

Mamelak AN, Rosenfeld S, Bucholz R, Raubitschek A, Nabors LB, Fiveash JB, Shen S, Khazaeli MB, Colcher D, Liu A, Osman M, Guthrie B, Schade-Bijur S, Hablitz DM, Alvarez VL, Gonda MA. Mamelak AN, et al. Among authors: shen s. J Clin Oncol. 2006 Aug 1;24(22):3644-50. doi: 10.1200/JCO.2005.05.4569. J Clin Oncol. 2006. PMID: 16877732 Clinical Trial.

2

Imaging glioma extent with 131I-TM-601.

Hockaday DC, Shen S, Fiveash J, Raubitschek A, Colcher D, Liu A, Alvarez V, Mamelak AN. Hockaday DC, et al. Among authors: shen s. J Nucl Med. 2005 Apr;46(4):580-6. J Nucl Med. 2005. PMID: 15809479 Free article. Clinical Trial.

3

Radiation dosimetry of 131I-chlorotoxin for targeted radiotherapy in glioma-bearing mice.

Shen S, Khazaeli MB, Gillespie GY, Alvarez VL. Shen S, et al. J Neurooncol. 2005 Jan;71(2):113-9. doi: 10.1007/s11060-004-0890-4. J Neurooncol. 2005. PMID: 15690125

4

Comparison of biodistribution, dosimetry, and outcome from clinical trials of radionuclide-CC49 antibody therapy.

Meredith R, Shen S, Macey D, Khazaeli MB, Carey D, Robert F, LoBuglio A. Meredith R, et al. Among authors: shen s. Cancer Biother Radiopharm. 2003 Jun;18(3):393-404. doi: 10.1089/108497803322285134. Cancer Biother Radiopharm. 2003. PMID: 12954125

5

A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.

Alvarez RD, Huh WK, Khazaeli MB, Meredith RF, Partridge EE, Kilgore LC, Grizzle WE, Shen S, Austin JM, Barnes MN, Carey D, Schlom J, LoBuglio AF. Alvarez RD, et al. Among authors: shen s. Clin Cancer Res. 2002 Sep;8(9):2806-11. Clin Cancer Res. 2002. PMID: 12231520 Clinical Trial.

6

Comparison of methods for predicting myelotoxicity for non-marrow targeting I-131-antibody therapy.

Shen S, Meredith RF, Duan J, Brezovich I, Khazaeli MB, LoBuglio AF. Shen S, et al. Cancer Biother Radiopharm. 2003 Apr;18(2):209-15. doi: 10.1089/108497803765036373. Cancer Biother Radiopharm. 2003. PMID: 12804046 Clinical Trial.

7

Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.

Shen S, Forero A, LoBuglio AF, Breitz H, Khazaeli MB, Fisher DR, Wang W, Meredith RF. Shen S, et al. J Nucl Med. 2005 Apr;46(4):642-51. J Nucl Med. 2005. PMID: 15809487 Free article. Clinical Trial.

8

Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy.

Shen S, Meredith RF, Duan J, Macey DJ, Khazaeli MB, Robert F, LoBuglio AF. Shen S, et al. J Nucl Med. 2002 Sep;43(9):1245-53. J Nucl Med. 2002. PMID: 12215566 Free article. Clinical Trial.

9

A novel monoclonal antibody design for radioimmunotherapy.

Forero A, Meredith RF, Khazaeli MB, Carpenter DM, Shen S, Thornton J, Schlom J, LoBuglio AF. Forero A, et al. Among authors: shen s. Cancer Biother Radiopharm. 2003 Oct;18(5):751-9. doi: 10.1089/108497803770418292. Cancer Biother Radiopharm. 2003. PMID: 14629823 Clinical Trial.

10

Intensity modulation with respiratory gating for radiotherapy of the pleural space.

Ahmed RS, Shen S, Ove R, Duan J, Fiveash JB, Russo SM. Ahmed RS, et al. Among authors: shen s. Med Dosim. 2007 Spring;32(1):16-22. doi: 10.1016/j.meddos.2006.10.002. Med Dosim. 2007. PMID: 17317531

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8,626 results

Search Page

Filters